Wilmington Savings Fund Society FSB Reduces Holdings in Amgen Inc.

Wilmington Savings Fund Society FSB has lowered its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.0% during the fourth quarter, according to the latest 13F filing with the Securities and Exchange Commission (SEC). After selling 1,274 shares throughout the quarter, the institutional investor currently holds 63,927 shares of the biopharmaceutical company. The value of Wilmington Savings Fund Society FSB's shares in Amgen amounted to $16,662,000 at the time of their most recent filing.

• MarketBeat Week in Review – 12/2 - 12/6

Additionally, several other institutional investors and hedge funds have made changes to their Amgen holdings. Notably, State Street Corp raised its stake in Amgen by 1.2% in the third quarter, bringing its total to 29,317,018 shares, valued at approximately $9,446,236,000 after acquiring 345,537 shares. Similarly, Geode Capital Management LLC increased its holdings in Amgen by 0.9%, now owning 12,122,889 shares worth $3,893,771,000 following a purchase of 103,851 shares.

Charles Schwab Investment Management Inc. also increased its position in Amgen by 2.4%, resulting in ownership of 10,532,629 shares valued at $3,393,718,000 after acquiring an additional 251,876 shares during the last quarter. Meanwhile, Janus Henderson Group PLC raised its stake in Amgen significantly by 11.7%, now holding 5,143,330 shares valued at $1,657,183,000 after buying 538,545 shares.

A noteworthy increase came from Pathway Financial Advisers LLC, which boosted its stake in Amgen by an astonishing 33,125.4%, now holding 4,460,181 shares valued at $1,437,115,000 after a massive addition of 4,446,757 shares. It is important to note that institutional investors collectively own about 76.50% of Amgen's stock.

Insider Trading Activity

In related news, insider transactions have also occurred within Amgen. Senior Vice President Nancy A. Grygiel sold 1,589 shares on February 5th at an average price of $304.47, totaling approximately $483,802.83. Post-sale, Grygiel retains a total of 7,210 shares valued at about $2,195,228.70, indicating an 18.06% decrease in her position. This transaction was disclosed in a filing with the SEC. Currently, insiders hold around 0.69% of the stock.

Analyst Ratings and Forecasts

Recent evaluations of Amgen have drawn a range of responses from analysts. A report from UBS Group indicated a reduction in their target price for Amgen from $335.00 to $326.00 while maintaining a neutral rating. Conversely, Jefferies Financial Group has reiterated a